426 results on '"Ullmann, Andrew"'
Search Results
52. Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease
53. In Vitro Evaluation of Radiolabeled Amphotericin B for Molecular Imaging of Mold Infections
54. Treatment of invasive fungal diseases in cancer patients—Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
55. Impact of immunosuppressive and antifungal drugs on PBMC- and whole blood-based flow cytometric CD154+ Aspergillus fumigatus specific T-cell quantification
56. Central nervous system disorders after hematopoietic stem cell transplantation: a prospective study of the Infectious Diseases Working Party of EBMT
57. Posaconazole concentrations in the central nervous system
58. Nephrotoxicity in the setting of invasive fungal diseases
59. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis
60. Leitlinie : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen
61. Leitlinie : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen
62. Pharmacokinetics of Oral Posaconazole in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Graft-versus-Host Disease
63. Efficacy of posaconazole and amphotericin B in experimental invasive pulmonary aspergillosis in dexamethasone immunosuppressed rats
64. Posaconazole Prophylaxis in Hematologic Cancer
65. Posaconazole Prophylaxis in Hematologic Cancer
66. Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
67. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia
68. Comment on: Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies
69. Sustained Complete Molecular Remissions After Treatment With Imatinib-Mesylate in Patients With Failure After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia: Results of a Prospective Phase II Open-Label Multicenter Study
70. Itraconazole versus Fluconazole for Antifungal Prophylaxis
71. Treatment of fungal infections in hematology and oncology
72. Voriconazole versus Liposomal Amphotericin B for Empirical Antifungal Therapy
73. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies
74. Leitlinie : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen
75. Development and evaluation of a whole blood-based approach for flow cytometric quantification of CD154+ mould-reactive T cells
76. Comparative Analysis of Inflammatory Cytokine Release and Alveolar Epithelial Barrier Invasion in a Transwell® Bilayer Model of Mucormycosis
77. Additional file 1: of Screening and contact precautions – A survey on infection control measures for multidrug-resistant bacteria in German university hospitals
78. Development and evaluation of a whole blood-based approach for flow cytometric quantification of CD154+ mould-reactive T cells.
79. Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO)
80. Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole
81. Susceptibility ofA. fumigatus-specific T-cell assays to pre-analytic blood storage and PBMC cryopreservation greatly depends on readout platform and analytes
82. Analysis of the in vitro activity of human neutrophils against Aspergillus fumigatus in presence of antifungal and immunosuppressive agents
83. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease
84. Stellungnahme zur Nutzenbewertung des IQWiG gemäß § 35a SGB V, Vorgangsnummer 2015-11-15-D-192, G-BA Bericht, veröffentlicht am 15. Februar 2016, IQWiG Bericht Nr. 360, veröffentlicht am 2. Februar 2016
85. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management
86. [Infectious diseases as a clinical specialty in Germany and Europe]
87. Invasive Pilzinfektionen: Nonresponder und Durchbruchinfektionen unter antimykotischer Medikation
88. Intra- and inter-individual variability ofAspergillus fumigatusreactive T-cell frequencies in healthy volunteers in dependency of mould exposure in residential and working environment
89. Mucorales spores induce a proinflammatory cytokine response in human mononuclear phagocytes and harbor no rodlet hydrophobins
90. Screening and contact precautions – A survey on infection control measures for multidrug-resistant bacteria in German university hospitals
91. Position paper on current aspects of sponsoring in accredited CME
92. Prospective Biomarker Screening for Diagnosis of Invasive Aspergillosis in High-Risk Pediatric Patients
93. The Epidemiology of Invasive Aspergillosis and Resistance Patterns of Aspergillus spp. in Germany - Interim Analysis of a Multicenter Observational Study
94. Clinical evidence for caspofungin monotherapy in the first‐line and salvage therapy of invasive Aspergillus infections
95. Hepatic Safety of Isavuconazole Compared With Voriconazole in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Complicated by Invasive Mold Disease: A Post-Hoc Analysis From the SECURE Study
96. Treatment of invasive fungal infections in cancer patients : updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
97. Stellungnahme zur Nutzenbewertung des IQWiG gemäß § 35a SGB V, Vorgangsnummer 2013-01-15-D-051, IQWiG Bericht Nr. 159, veröffentlicht am 15. April 2013
98. Susceptibility of A. fumigatus‐specific T‐cell assays to pre‐analytic blood storage and PBMC cryopreservation greatly depends on readout platform and analytes.
99. Analysis of the in vitro activity of human neutrophils against Aspergillus fumigatus in presence of antifungal and immunosuppressive agents.
100. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.